Navigation Links
CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection
Date:5/11/2011

rable plasma viremia at baseline, and had viral load data available at > 2 weeks after the first dose of CMX001.  The majority of CMX001 treated patients had a > 99 percent decrease in viral load compared to baseline after two weeks of therapy.  There was a median -2.5 log10 change in viremia from baseline by the last timepoint (range -6.0 to +0.3 log10).  Patients who had either sensitive virus or no proven resistance had a median decrease of almost 1000-fold (-2.9 log10) from baseline.  In patients with pre-existing resistance to CDV, attributable to prior suboptimal cidofovir (CDV) therapy, antiviral activity of CMX001 was a median -0.55 log10 decrease from baseline. Additionally, higher plasma exposure to CMX001 appeared to correlate with a more rapid response.  

These data were presented by Randall Lanier, PhD, Senior Director of Virology, Chimerix, at the 24th Annual International Conference on Antiviral Research in an oral presentation titled “CMX001 (Hexadecyloxypropyl Cidofovir) Antiviral Activity against Adenovirus in Patients Correlates with Drug Levels and Viral Sensitivity” (Abstract # 33).  

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company’s lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 475 people have received CMX001 to date, with a growing body of evidence supporting the drug’s antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pe
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
2. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
3. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
4. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
5. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment
8. Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
9. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
10. Tissue Engineering Shows Promise to Revolutionize Transplant Medicine
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 30, 2014 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... technology and its lead drug candidate, aldoxorubicin.  The ... A New Approach," will be given by ... the Sarcoma Oncology Center and principal investigator of ...
(Date:10/30/2014)... October 30, 2014 ... beim Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie ... bei Säuglingen und Kleinkindern. Der bisher übliche ... Ernährung der Babys bzw. deren stillenden Mütter ... dass sich bei einer beträchtlichen Anzahl von ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... Selective Kinase Inhibitor Phase 1 Trial in ... 9, 2008 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases, ... 1, dose-escalation study for its,selective kinase inhibitor, ...
... 2008 The Association,for Professionals in Infection Control ... MT, MPH, of Albany, NY, has been named,the ... Award.,APIC presents the annual award to an infection ... of Carole DeMille, a pioneer,in infection control. The ...
Cached Medicine Technology:EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... News) -- When it comes to heart disease, a new ... care when they have symptoms that spell trouble. "The ... with a more severe or advanced stage of heart disease, ... Kreatsoulas, a Fulbright Scholar and research fellow at the Harvard ... the Heart and Stroke Foundation of Canada. In the ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Americans, opinions about ... lines, a new study finds. Democratic voters are ... according to the researchers. Almost three-quarters of Democrats want ... Thirty percent want Congress to implement the current law, ... the ACA. Among Independent voters, one-third want the ...
(Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
Breaking Medicine News(10 mins):Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3
... Southwestern Medical Center maternal-fetal specialists have confirmed a potential ... risk for hepatitis B, a health problem that affects ... vaccination schedule for high-risk pregnant women was found effective ... Obstetrics & Gynecology . While the normal three-shot ...
... , MONDAY, June 27 (HealthDay News) -- Certain groups ... poorer outcomes and higher death rates than those treated ... study. Nearly five million people live in U.S. ... Northern Mariana Islands and the U.S. Virgin Islands, according ...
... childhood cancer survivors found that the first cancer is ... forms of the disease for about 10 percent of ... in the federally funded Childhood Cancer Survivor Study (CCSS). ... reported that 1,382, or 9.6 percent, of survivors developed ...
... 27 (HealthDay News) -- Uncovering some science behind the type ... and Canadian researchers reports that a woman can tell whether ... face when she is ovulating. Women also appear to ... they start to harbor romantic notions or mating aspirations, the ...
... Scientists have long known that, to form tissue structures ... the other cells, matrix, and signals in their environment. But ... to distinguish between normal and pathological behaviors. A team of ... to evaluate human stem cells using cell micropatterning a ...
... HealthDay Reporter , MONDAY, June 27 (HealthDay News) -- ... both by violent media content and greater evening use of ... Reviewing parent surveys and media diaries from 617 preschoolers, Seattle ... was linked to a significant jump in sleep problems, as ...
Cached Medicine News:Health News:Stepped-up vaccine series for hepatitis B is effective during pregnancy 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 3Health News:Does Ovulation Boost a Woman's 'Gaydar'? 2Health News:Tiny cell patterns reveal the progression of development and disease 2Health News:Tiny cell patterns reveal the progression of development and disease 3Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 2Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 3
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Straight shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: